{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-24-006382","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2024-09-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.501632+00:00","generated_at":"2026-05-31T02:48:13.984080+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"medium","headline":"Zeo ScientifiX completes Phase 1 trials for Zofin; seeks Phase 2 trials","bullets":["Completed Phase 1 clinical trials for flagship product Zofin; actively seeking to commence Phase 2 trials for multiple indications.","Partnered with Exotropin to develop topical aesthetic and anti-aging products using exosome technology; holds minority stake.","Changed name from Organicell Regenerative Medicine to Zeo ScientifiX in February 2024 to reflect scientific focus.","Regenerative medicine market projected to grow to $175B by 2032 at 22.8% CAGR, per Precedence Research."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-24-006382","json":"https://secwatch.observer/filing/0001829126-24-006382.json","markdown":"https://secwatch.observer/filing/0001829126-24-006382.md","text":"https://secwatch.observer/filing/0001829126-24-006382.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912624006382/0001829126-24-006382-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912624006382/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T02:48:13.984080+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}